Skip to main content

ENGLISH · EVIDENCE OVERVIEW

Urofollitropin
evidence profile

Purified human follicle-stimulating hormone extracted from postmenopausal urine. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

Urofollitropin: conceptual scientific illustration for Reproductive Endocrinology
VISUAL GUIDE · Urofollitropin

Reproductive Endocrinology

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

A purified human FSH preparation extracted from postmenopausal urine, not recombinant FSH or menotropins. Thai FOSOH records and the discontinued, voluntarily revoked US BRAVELLE licence are product- and jurisdiction-specific; controlled IVF comparisons do not establish blanket interchangeability.

01

ENTITY FACTS

What should readers identify first?

MOLECULEUrofollitropin
PHARMACOLOGYPurified human follicle-stimulating hormone extracted from postmenopausal urine
PRIMECORE CLASSA
EVIDENCE GRADEA
RESEARCH TOPICReproductive Endocrinology
LAST REVIEWED2026-08-29

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

Insufficient data in the current dataset

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. https://ndi.fda.moph.go.th/drug_detail/index/?rcno=4800044&rctype=1C&register=MUMgNDQvNDg%3D
  2. https://purplebooksearch.fda.gov/index.cfm?blaNo=021289&event=productdetails
  3. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-289_Bravelle_chemr.pdf
  4. https://pubmed.ncbi.nlm.nih.gov/12057729/
  5. https://pubmed.ncbi.nlm.nih.gov/18367182/
  6. https://pubmed.ncbi.nlm.nih.gov/10783345/
  7. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is Urofollitropin?

Urofollitropin is described pharmacologically as Purified human follicle-stimulating hormone extracted from postmenopausal urine. A purified human FSH preparation extracted from postmenopausal urine, not recombinant FSH or menotropins. Thai FOSOH records and the discontinued, voluntarily revoked US BRAVELLE licence are product- and jurisdiction-specific; controlled IVF comparisons do not establish blanket interchangeability.

Does Urofollitropin have strong evidence?

PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is Urofollitropin approved everywhere?

No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice